Crestline Management LP Buys Shares of 172,202 Replimune Group, Inc. (NASDAQ:REPL)

Crestline Management LP bought a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 172,202 shares of the company's stock, valued at approximately $2,085,000. Crestline Management LP owned approximately 0.25% of Replimune Group at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after acquiring an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd boosted its stake in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after acquiring an additional 8,183 shares in the last quarter. XTX Topco Ltd purchased a new stake in Replimune Group in the fourth quarter worth about $137,000. Finally, Freestone Grove Partners LP bought a new position in shares of Replimune Group during the fourth quarter valued at approximately $140,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. HC Wainwright boosted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. BMO Capital Markets raised their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $19.43.

Replimune Group Stock Performance

REPL traded down $0.32 during midday trading on Tuesday, hitting $7.54. 258,089 shares of the company traded hands, compared to its average volume of 840,846. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The company's 50-day moving average is $9.27 and its 200 day moving average is $11.45. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The firm has a market capitalization of $580.69 million, a PE ratio of -2.46 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.